0RAG Stock Chart & Stats
€3.55
€0.05(4.00%)
At close: 4:00 PM EST
€3.55
€0.05(4.00%)
Day’s Range― - ―
52-Week Range€1.45 - €5.21
Previous CloseN/A
Volume167.00
Average Volume (3M)1.33K
Market Cap
€78.58M
Enterprise Value€92.33M
Total Cash (Recent Filing)€3.52M
Total Debt (Recent Filing)€3.81M
Price to Earnings (P/E)―
Beta0.26
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding42,568,070
10 Day Avg. Volume331
30 Day Avg. Volume1,335
Financial Highlights & Ratios
PEG Ratio-1.03
Price to Book (P/B)31.58
Price to Sales (P/S)33.12
P/FCF Ratio-42.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.46
Revenue Forecast (FY)€4.66M
Bulls Say, Bears Say
Bulls Say
Focused R&D PlatformABIONYX’s concentrated scientific focus on apoA‑I biology and related therapeutic candidates creates durable differentiation in inflammatory and infectious indications (including sepsis). A clear, specialized platform supports translational continuity, targeted trial design, and potential for partnership value creation over months.
Revenue Recovery TrendAlthough revenue remains small and volatile, the move from near-zero toward materially higher receipts signals nascent commercial or collaboration traction. This trend, if sustained, can provide incremental funding for development, validate program progress, and reduce absolute dependence on external financing over the medium term.
Improving Operating Cash BurnOperating cash outflows narrowed in 2025 versus 2024, indicating management is starting to slow cash depletion through cost control, milestone timing or better receipts. A continued reduction in burn rate would extend runway and improve optionality for financing or partnerships over the next several months.
Bears Say
Persistent Negative Cash GenerationSustained negative operating and free cash flow means the company must repeatedly access external capital to fund operations and trials. That reliance increases dilution or debt risk, constrains strategic flexibility, and creates recurring execution risk until a durable positive cash generation pathway is established.
Sharp Margin Deterioration And Heavy LossesA marked decline in gross margin and intensely negative EBIT margin indicate worsening unit economics or rising development costs relative to revenue. Such structural profitability deterioration undermines the path to self-sustaining operations and increases dependence on financing or partner deals to support pipeline progress.
Eroding Equity And Rising LeverageMaterial equity erosion combined with rising debt-to-equity reduces financial flexibility and raises the cost and difficulty of funding future clinical programs. Greater leverage increases solvency risk and can lead to restrictive covenants or unfavorable financing terms, constraining strategic choices over the medium term.
0RAG FAQ
What was ABIONYX Pharma SA’s price range in the past 12 months?
ABIONYX Pharma SA lowest share price was €1.45 and its highest was €5.21 in the past 12 months.
What is ABIONYX Pharma SA’s market cap?
ABIONYX Pharma SA’s market cap is €78.58M.
When is ABIONYX Pharma SA’s upcoming earnings report date?
ABIONYX Pharma SA’s upcoming earnings report date is Sep 24, 2026 which is in 52 days.
How were ABIONYX Pharma SA’s earnings last quarter?
ABIONYX Pharma SA released its earnings results on Mar 12, 2026. The company reported -€0.091 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.091.
Is ABIONYX Pharma SA overvalued?
According to Wall Street analysts ABIONYX Pharma SA’s price is currently Overvalued.
Does ABIONYX Pharma SA pay dividends?
ABIONYX Pharma SA does not currently pay dividends.
What is ABIONYX Pharma SA’s EPS estimate?
ABIONYX Pharma SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ABIONYX Pharma SA have?
ABIONYX Pharma SA has 42,568,070 shares outstanding.
What happened to ABIONYX Pharma SA’s price movement after its last earnings report?
ABIONYX Pharma SA reported an EPS of -€0.091 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.069%.
Which hedge fund is a major shareholder of ABIONYX Pharma SA?
Currently, no hedge funds are holding shares in GB:0RAG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ABIONYX Pharma SA
ABIONYX Pharma SA is a biotechnology company dedicated to the identification and advancement of therapies for conditions affecting the kidneys and eyes. The firm's pipeline includes CER-001, an innovative negatively-charged lipoprotein particle. This compound is designed to mimic the structural and functional attributes of pre-beta HDL, utilizing human recombinant apoA-I (a natural high-density lipoprotein protein) along with natural phospholipids like sphingomyelin and dipalmitoylphosphatidylglycerol. CER-001 is currently under development for patients recovering from acute coronary syndrome and those with familial primary hypoalphalipoproteinemia. Another key candidate, CER-002, is a specific agonist for peroxisome proliferator-activated receptor delta, targeting cardiovascular and metabolic diseases. Additionally, CER-209 is being developed as a potential treatment for metabolic liver diseases, atherosclerosis, and non-alcoholic steatohepatitis (NASH). ABIONYX maintains strategic partnerships with GTP Biologics and VBI Therapeutics Group for the bioproduction of its bio-HDL in France. Established in 2005, the company operated as Cerenis Therapeutics Holding SA before its rebranding to ABIONYX Pharma SA in August 2019. Its operations are headquartered in Balma, France.